Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-native individuals
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| Texto Completo: | http://hdl.handle.net/10362/125098 |
Resumo: | Publisher Copyright: © 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. |
| id |
RCAP_3ef4ec82846ecc8a0e032a2a7cf2a333 |
|---|---|
| oai_identifier_str |
oai:run.unl.pt:10362/125098 |
| network_acronym_str |
RCAP |
| network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository_id_str |
7160 |
| spelling |
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-native individualsResults from a European multi-cohort studyPharmacologyMicrobiology (medical)Infectious DiseasesPharmacology (medical)SDG 3 - Good Health and Well-beingSDG 9 - Industry, Innovation, and InfrastructureSDG 12 - Responsible Consumption and ProductionPublisher Copyright: © 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.Background: INSTIs have become a pillar of first-line ART. Real-world data are needed to assess their effectiveness in routine care. Objectives: We analysed ART-naive patients who started INSTI-based regimens in 2012-19 whose data were collected by INTEGRATE, a European collaborative study including seven national cohorts. Methods: Kaplan-Meier analyses assessed time to virological failure (VF), defined as one viral load (VL) ≥1000 copies/mL, two consecutive VLs ≥50 copies/mL, or one VL ≥50 copies/mL followed by treatment change after ≥24 weeks of follow-up, and time to INSTIs discontinuation (INSTI-DC) for any reason. Factors associated with VF and INSTI-DC were explored by logistic regression analysis. Results: Of 2976 regimens started, 1901 (63.9%) contained dolutegravir, 631 (21.2%) elvitegravir and 444 (14.9%) raltegravir. The 1 year estimated probabilities of VF and INSTI-DC were 5.6% (95% CI 4.5-6.7) and 16.2% (95% CI 14.9-17.6), respectively, and were higher for raltegravir versus both elvitegravir and dolutegravir. A baseline VL ≥100 000 copies/mL [adjusted HR (aHR) 2.17, 95% CI 1.55-3.04, P < 0.001] increased the risk of VF, while a pre-treatment CD4 count ≥200 cells/mm3 reduced the risk (aHR 0.52, 95% CI 0.37-0.74, P < 0.001). Predictors of INSTI-DC included use of raltegravir versus dolutegravir (aHR 3.03, 95% CI 2.34-3.92, P < 0.001), use of >3 drugs versus 3 drugs (aHR 2.73, 95% CI 1.55-4.79, P < 0.001) and starting ART following availability of dolutegravir (aHR 0.64, 95% CI 0.48-0.83, P = 0.001). Major INSTI mutations indicative of transmitted drug resistance occurred in 2/1114 (0.2%) individuals. Conclusions: This large multi-cohort study indicates high effectiveness of elvitegravir- or dolutegravir-based first-line ART in routine practice across Europe.TB, HIV and opportunistic diseases and pathogens (THOP)Global Health and Tropical Medicine (GHTM)Instituto de Higiene e Medicina Tropical (IHMT)RUNRossetti, BarbaraFabbiani, MassimilianoDi Carlo, DomenicoIncardona, F.Abecasis, A.Gomes, PerpetuaGeretti, A. M.Seguin-Devaux, C.Garcia, FedericoKaiser, RolfModica, SaraShallvari, AdrianSönnerborg, A.Zazzi, M.Bobkova, M.Seguin-Devaux, C.Paredes, R.Sayan, M.Vandamme, A. M.2021-09-24T02:25:09Z2021-09-012021-09-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article6application/pdfhttp://hdl.handle.net/10362/125098eng0305-7453PURE: 33793803https://doi.org/10.1093/jac/dkab200info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T17:56:23Zoai:run.unl.pt:10362/125098Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T17:56:23Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
| dc.title.none.fl_str_mv |
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-native individuals Results from a European multi-cohort study |
| title |
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-native individuals |
| spellingShingle |
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-native individuals Rossetti, Barbara Pharmacology Microbiology (medical) Infectious Diseases Pharmacology (medical) SDG 3 - Good Health and Well-being SDG 9 - Industry, Innovation, and Infrastructure SDG 12 - Responsible Consumption and Production |
| title_short |
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-native individuals |
| title_full |
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-native individuals |
| title_fullStr |
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-native individuals |
| title_full_unstemmed |
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-native individuals |
| title_sort |
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-native individuals |
| author |
Rossetti, Barbara |
| author_facet |
Rossetti, Barbara Fabbiani, Massimiliano Di Carlo, Domenico Incardona, F. Abecasis, A. Gomes, Perpetua Geretti, A. M. Seguin-Devaux, C. Garcia, Federico Kaiser, Rolf Modica, Sara Shallvari, Adrian Sönnerborg, A. Zazzi, M. Bobkova, M. Paredes, R. Sayan, M. Vandamme, A. M. |
| author_role |
author |
| author2 |
Fabbiani, Massimiliano Di Carlo, Domenico Incardona, F. Abecasis, A. Gomes, Perpetua Geretti, A. M. Seguin-Devaux, C. Garcia, Federico Kaiser, Rolf Modica, Sara Shallvari, Adrian Sönnerborg, A. Zazzi, M. Bobkova, M. Paredes, R. Sayan, M. Vandamme, A. M. |
| author2_role |
author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
TB, HIV and opportunistic diseases and pathogens (THOP) Global Health and Tropical Medicine (GHTM) Instituto de Higiene e Medicina Tropical (IHMT) RUN |
| dc.contributor.author.fl_str_mv |
Rossetti, Barbara Fabbiani, Massimiliano Di Carlo, Domenico Incardona, F. Abecasis, A. Gomes, Perpetua Geretti, A. M. Seguin-Devaux, C. Garcia, Federico Kaiser, Rolf Modica, Sara Shallvari, Adrian Sönnerborg, A. Zazzi, M. Bobkova, M. Seguin-Devaux, C. Paredes, R. Sayan, M. Vandamme, A. M. |
| dc.subject.por.fl_str_mv |
Pharmacology Microbiology (medical) Infectious Diseases Pharmacology (medical) SDG 3 - Good Health and Well-being SDG 9 - Industry, Innovation, and Infrastructure SDG 12 - Responsible Consumption and Production |
| topic |
Pharmacology Microbiology (medical) Infectious Diseases Pharmacology (medical) SDG 3 - Good Health and Well-being SDG 9 - Industry, Innovation, and Infrastructure SDG 12 - Responsible Consumption and Production |
| description |
Publisher Copyright: © 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021-09-24T02:25:09Z 2021-09-01 2021-09-01T00:00:00Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/125098 |
| url |
http://hdl.handle.net/10362/125098 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
0305-7453 PURE: 33793803 https://doi.org/10.1093/jac/dkab200 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
6 application/pdf |
| dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
| instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| instacron_str |
RCAAP |
| institution |
RCAAP |
| reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| repository.mail.fl_str_mv |
mluisa.alvim@gmail.com |
| _version_ |
1817545823523700736 |